May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Squamous Cell Carcinoma in situ of the Eyelid Successfully Treated With Imiquimod
Author Affiliations & Notes
  • P.A. Brannan
    Ophthalmology,
    Univ Cincinnati, Cincinnati, OH
  • H.K. Anderson
    Dermatology,
    Univ Cincinnati, Cincinnati, OH
  • R.C. Kersten
    Ophthalmology,
    Univ Cincinnati, Cincinnati, OH
  • D.R. Kulwin
    Ophthalmology,
    Univ Cincinnati, Cincinnati, OH
  • Footnotes
    Commercial Relationships  P.A. Brannan, None; H.K. Anderson, None; R.C. Kersten, None; D.R. Kulwin, None.
  • Footnotes
    Support  Research to Prevent Blindness
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 5401. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P.A. Brannan, H.K. Anderson, R.C. Kersten, D.R. Kulwin; Squamous Cell Carcinoma in situ of the Eyelid Successfully Treated With Imiquimod . Invest. Ophthalmol. Vis. Sci. 2005;46(13):5401.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To present a rare case of squamous cell carcinoma in situ (Bowen's disease) affecting the eyelid that was successfully treated with imiquimod.The clinical presentation, histopathology and treatment are presented. The immunomodulatory effects of imiquimod are described in detail. Methods: Chart review Results:Biopsy proven squamous cell carcinoma in situ only involving the entire left lower eyelid was treated with imiquimod for three months. After treatment, the tumor resolved both clinically and histopathologically. There was no evidence of recurrence six months after treatment cessation. Conclusions:Imiquimod produces indirect antitumor activity by stimulating the cell–mediated immune response and local cytokine production. This represents a novel treatment for periocular tumors and may be safely used on the eyelid. Potential benefits include avoiding extensive periocular tumor excision and reconstruction in patients with squamous cell carcinoma in situ.

Keywords: eyelid • immunomodulation/immunoregulation • tumors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×